CN115515680A - 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法 - Google Patents

用于评估神经递质转运蛋白抑制剂的功效的组合物和方法 Download PDF

Info

Publication number
CN115515680A
CN115515680A CN202180031602.1A CN202180031602A CN115515680A CN 115515680 A CN115515680 A CN 115515680A CN 202180031602 A CN202180031602 A CN 202180031602A CN 115515680 A CN115515680 A CN 115515680A
Authority
CN
China
Prior art keywords
snp
snps
treatment
transporter
norepinephrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031602.1A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·W·惠特克
扎夫林·达利
孙红
卢海平
李晓军
威尔逊·吴
罗文�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suoyuan Biomedicine Co ltd
Original Assignee
Suoyuan Biomedicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suoyuan Biomedicine Co ltd filed Critical Suoyuan Biomedicine Co ltd
Publication of CN115515680A publication Critical patent/CN115515680A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202180031602.1A 2020-03-06 2021-02-23 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法 Pending CN115515680A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
US62/986,603 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (1)

Publication Number Publication Date
CN115515680A true CN115515680A (zh) 2022-12-23

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031602.1A Pending CN115515680A (zh) 2020-03-06 2021-02-23 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法

Country Status (13)

Country Link
US (1) US12612661B2 (https=)
EP (1) EP4106872A4 (https=)
JP (1) JP2023515665A (https=)
KR (1) KR20230005816A (https=)
CN (1) CN115515680A (https=)
AR (1) AR121515A1 (https=)
AU (1) AU2021231683A1 (https=)
BR (1) BR112022017770A2 (https=)
CA (1) CA3174572A1 (https=)
IL (1) IL296168A (https=)
MX (1) MX2022010816A (https=)
TW (1) TW202146660A (https=)
WO (1) WO2021178166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128884A1 (en) * 2003-12-02 2007-06-07 Japan Science And Technology Agency Metal oxynitride electrode catalyst
US20080065544A1 (en) * 1996-05-10 2008-03-13 Barcelou David M Automated transaction machine
US20110189663A1 (en) * 2007-03-05 2011-08-04 Cancer Care Ontario Assessment of risk for colorectal cancer
US20130132114A1 (en) * 2010-11-05 2013-05-23 Jay L. Lombard Neuropsychiatric test reports
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
CN106536752A (zh) * 2014-03-14 2017-03-22 凯尔迪克斯公司 用于在移植受体中监测免疫抑制疗法的方法
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2707498B1 (en) 2011-01-31 2018-01-17 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2838207A1 (en) 2011-06-08 2012-12-13 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid x receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080065544A1 (en) * 1996-05-10 2008-03-13 Barcelou David M Automated transaction machine
US20070128884A1 (en) * 2003-12-02 2007-06-07 Japan Science And Technology Agency Metal oxynitride electrode catalyst
US20110189663A1 (en) * 2007-03-05 2011-08-04 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US20130132114A1 (en) * 2010-11-05 2013-05-23 Jay L. Lombard Neuropsychiatric test reports
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
CN106536752A (zh) * 2014-03-14 2017-03-22 凯尔迪克斯公司 用于在移植受体中监测免疫抑制疗法的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOGUE等: "The ankyrin-3 gene is associated with posttraumatic stress disorder and externalizing comorbidity", 《PSYCHOENDOCRINOLOGY》, vol. 38, no. 10, 21 June 2013 (2013-06-21), pages 2249 - 2257 *

Also Published As

Publication number Publication date
US12612661B2 (en) 2026-04-28
WO2021178166A1 (en) 2021-09-10
CA3174572A1 (en) 2021-09-10
US20230193388A1 (en) 2023-06-22
MX2022010816A (es) 2022-12-13
BR112022017770A2 (pt) 2022-11-29
JP2023515665A (ja) 2023-04-13
TW202146660A (zh) 2021-12-16
EP4106872A4 (en) 2024-04-10
EP4106872A1 (en) 2022-12-28
KR20230005816A (ko) 2023-01-10
IL296168A (en) 2022-11-01
AU2021231683A1 (en) 2022-09-22
AR121515A1 (es) 2022-06-08

Similar Documents

Publication Publication Date Title
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
US12612661B2 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
US20120309641A1 (en) Diagnostic kits, genetic markers, and methods for scd or sca therapy selection
WO2017161289A1 (en) Method for identifying clinical trial responders from a placebo group in major depression
HK1196399A (en) Method for discovering pharmacogenomic biomarkers
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: The United States of California, San Diego

Applicant after: Suoyuan biomedical (USA) Co.,Ltd.

Address before: The United States of California, San Diego

Applicant before: Suoyuan Biomedicine Co.,Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083504

Country of ref document: HK